TABLE I.
Characteristics of Cases Surviving at 5 Years After Diagnosis and Controls.
| Cases |
||||||
|---|---|---|---|---|---|---|
| Hypopharynx, n = 23 | Larynx, n = 283 | Oral Cavity, n = 115 | Oropharynx, n = 236 | Controls, n = 1,250 | Overall, N = 1,907 | |
| Age at enrollment, yr, no. (%) | ||||||
| ≤50 | 6 (26.1) | 52 (18.4) | 22 (19.1) | 76 (32.2) | 181 (14.5) | 337 (17.7) |
| 51–65 | 11 (47.8) | 149 (52.7) | 58 (50.4) | 129 (54.7) | 538 (43.0) | 885 (46.4) |
| 66+ | 6 (26.1) | 82 (29.0) | 35 (30.4) | 31 (13.1) | 531 (42.5) | 685 (35.9) |
| Race, no. (%) | ||||||
| White | 12 (52.2) | 202 (71.4) | 89 (77.4) | 193 (81.8) | 1,000 (80.0) | 1,496 (78.4) |
| Black | 10 (43.5) | 76 (26.9) | 25 (21.7) | 34 (14.4) | 233 (18.6) | 378 (19.8) |
| Other | 1 (4.3) | 5 (1.8) | 1 (0.9) | 9 (3.8) | 17 (1.4) | 33 (1.7) |
| Sex, no. (%) | ||||||
| Male | 20 (87.0) | 224 (79.2) | 73 (63.5) | 194 (82.2) | 853 (68.2) | 1,364 (71.5) |
| Female | 3 (13.0) | 59 (20.8) | 42 (36.5) | 42 (17.8) | 397 (31.8) | 543 (28.5) |
| Smoking, no. (%) | ||||||
| < 10 pack-years | 4 (18.2) | 29 (10.2) | 22 (19.1) | 93 (39.7) | 718 (57.5) | 866 (45.5) |
| ≥10 pack-years | 18 (81.8) | 254 (89.8) | 93 (80.9) | 141 (60.3) | 530 (42.5) | 1,036 (54.5) |
| NA | 1 | 0 | 0 | 2 | 2 | 3 |
| Education, no. (%) | ||||||
| <HS | 11 (47.8) | 107 (37.8) | 36 (31.3) | 39 (16.5) | 174 (13.9) | 367 (19.2) |
| HS | 5 (21.7) | 80 (28.3) | 33 (28.7) | 64 (27.1) | 298 (23.8) | 480 (25.2) |
| >HS | 7 (30.4) | 96 (33.9) | 46 (40.0) | 133 (56.4) | 778 (62.2) | 1,060 (55.6) |
| Private insurance, no. (%) | ||||||
| No | 11 (52.4) | 141 (50.7) | 50 (51.0) | 62 (27.3) | 463 (37.6) | 727 (39.2) |
| Yes | 10 (47.6) | 137 (49.3) | 48 (49.0) | 165 (72.7) | 769 (62.4) | 1,129 (60.8) |
| NA | 2 | 5 | 17 | 9 | 18 | 33 |
| Income, no. (%) | ||||||
| >$50,000 | 5 (22.7) | 80 (29.2) | 29 (26.4) | 110 (48.2) | 553 (45.9) | 777 (42.2) |
| $20,000–$50,000 | 8 (36.4) | 105 (38.3) | 46 (41.8) | 70 (30.7) | 431 (35.7) | 660 (35.9) |
| <$20,000 | 9 (40.9) | 89 (32.5) | 35 (31.8) | 48 (21.1) | 222 (18.4) | 403 (21.9) |
| NA | 1 | 9 | 5 | 8 | 44 | 23 |
| Stage, no. (%) | ||||||
| I | 3 (13.0) | 112 (39.6) | 45 (39.1) | 18 (7.6) | — | 178 (9.3) |
| II | 4 (17.4) | 67 (23.7) | 26 (22.6) | 19 (8.1) | — | 116 (6.1) |
| III | 4 (17.4) | 49 (17.3) | 7 (6.1) | 54 (22.9) | — | 114 (6.0) |
| IV | 12 (52.2) | 55 (19.4) | 37 (32.2) | 145 (61.4) | — | 249 (13.1) |
| Treatment, no. (%) | ||||||
| Chemo + radiation | 15 (65.2) | 52 (18.4) | 9 (7.8) | 78 (33.2) | — | 154 (8.1) |
| Chemo + radiation + surgery | 1 (4.3) | 12 (4.2) | 13 (11.3) | 74 (31.5) | — | 100 (5.2) |
| Radiation only | 4 (17.4) | 97 (34.3) | 5 (4.3) | 15 (6.4) | — | 121 (6.3) |
| Radiation + surgery | 3 (13.0) | 72 (25.4) | 17 (14.8) | 46 (19.6) | — | 138 (7.2) |
| Surgery only | 0 (0.0) | 50 (17.7) | 71 (61.7) | 22 (9.4) | — | 143 (7.5) |
| NA | 0 | 0 | 0 | 1 | 1 | |
HS = high school; NA = not available.